Agnieszka Adamczyk
Overview
Explore the profile of Agnieszka Adamczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urbiola-Salvador V, Jablonska A, Miroszewska D, Kamysz W, Duzowska K, Drezek-Chyla K, et al.
Biomark Insights
. 2024 Jun;
19:11772719241257739.
PMID: 38911905
Background: Colorectal cancer (CRC) prognosis is determined by the disease stage with low survival rates for advanced stages. Current CRC screening programs are mainly using colonoscopy, limited by its invasiveness...
2.
Stankowska W, Sarkisyan D, Bruhn-Olszewska B, Duzowska K, Bienkowski M, Jakalski M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473323
Bladder urothelial carcinoma (BLCA) is the 10th most common cancer with a low survival rate and strong male bias. We studied the field cancerization in BLCA using multi-sample- and multi-tissue-per-patient...
3.
Christopoulos P, Girard N, Proto C, Soares M, Lopez P, van der Wekken A, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001589
Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene () Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need...
4.
Urbiola-Salvador V, Jablonska A, Miroszewska D, Huang Q, Duzowska K, Drezek-Chyla K, et al.
Front Oncol
. 2023 May;
13:1158261.
PMID: 37228491
Introduction: Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of death worldwide. Efficient non-invasive blood-based biomarkers for CRC early detection and prognosis are urgently...
5.
Madej E, Brozyna A, Adamczyk A, Wronski N, Harazin-Lechowska A, Muzyk A, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765875
Vemurafenib and dabrafenib are BRAF kinase inhibitors (BRAFi) used for the treatment of patients with melanoma carrying the V600E BRAF mutation. However, melanoma cells develop resistance to both drugs when...
6.
Puskulluoglu M, Grela-Wojewoda A, Szczubialka G, Zemelka T, Lompart J, Salek-Zan A, et al.
Eur J Cancer
. 2022 Nov;
178:234-242.
PMID: 36371305
Background: On 24th of February 2022, Ukrainian cancer patients had to face a new war. Here we describe an experience of the Maria Sklodowska-Curie National Research Institute of Oncology Branch...
7.
Grela-Wojewoda A, Puskulluoglu M, Sas-Korczynska B, Zemelka T, Pacholczak-Madej R, Wysocki W, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884413
Trastuzumab-induced cardiotoxicity (TIC) can lead to early treatment discontinuation. The aim of this study was to evaluate: N-terminal brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), myoglobin, and selected biochemical and...
8.
Filipowicz N, Drezek K, Horbacz M, Wojdak A, Szymanowski J, Rychlicka-Buniowska E, et al.
PLoS One
. 2022 Apr;
17(4):e0266111.
PMID: 35390022
The progress in translational cancer research relies on access to well-characterized samples from a representative number of patients and controls. The rationale behind our biobanking are explorations of post-zygotic pathogenic...
9.
Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, Puskulluoglu M
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269958
Kinase inhibitors (KIs) represent a growing class of drugs directed at various protein kinases and used in the treatment of both solid tumors and hematologic malignancies. It is a heterogeneous...
10.
Grela-Wojewoda A, Niemiec J, Sas-Korczynska B, Zemelka T, Puskulluoglu M, Wysocki W, et al.
Pol Arch Intern Med
. 2022 Jan;
132(4).
PMID: 35089680
Introduction: Recently, the prognosis of patients with HER2‑positive breast cancer (BC) has improved significantly owing to the use of combined treatment modalities. However, systemic treatment is as-sociated with increased risk...